The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.